ALTIMMUNE, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.180 USD | +12.54% |
|
+13.87% | -35.42% |
| 08-15 | Altimmune, Inc. Announces That David J. Drutz Will Not Stand for Re-Election to the Board | CI |
| 08-08 | Transcript : Altimmune, Inc., Q2 2024 Earnings Call, Aug 08, 2024 |
Company Valuation: Altimmune, Inc.
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 28.38 | 417 | 363.1 | 808.4 | 604.4 | 453.4 | - | - |
| Change | - | 1,369.44% | -12.92% | 122.62% | -25.23% | -24.98% | - | - |
| Enterprise Value (EV) 1 | 28.38 | 417 | 363.1 | 697.3 | 469.3 | 437.9 | 245.6 | 357.9 |
| Change | - | 1,369.44% | -12.92% | 92.02% | -32.7% | -6.7% | -43.9% | 45.69% |
| P/E ratio | -1.18x | -5.91x | -3.9x | -9.09x | -6.78x | -7.75x | -5.49x | -3.74x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.3x | -0.2x | 0.4x | 0.82x | 0.2x | -0.1x | -0.1x |
| Capitalization / Revenue | 4.89x | 50.9x | 82.3x | -11,889x | 1,419x | 14.5x | 18.1x | - |
| EV / Revenue | 4.89x | 50.9x | 82.3x | -10,255x | 1,102x | 14x | 9.83x | - |
| EV / EBITDA | - | - | -3.77x | -7.93x | - | -4.42x | -2.23x | -2.97x |
| EV / EBIT | -1.32x | -7.61x | -4.25x | -7.95x | -5.62x | -6.96x | -2.32x | -2.06x |
| EV / FCF | - | -12x | -4.02x | -11.1x | -6.19x | -5.65x | -2.68x | -2.08x |
| FCF Yield | - | -8.31% | -24.9% | -8.99% | -16.2% | -17.7% | -37.4% | -48.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.6 | -1.91 | -2.35 | -1.81 | -1.66 | -0.8233 | -1.162 | -1.708 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.801 | 8.185 | 4.41 | -0.068 | 0.426 | 31.25 | 25 | - |
| EBITDA 1 | - | - | -96.36 | -87.94 | - | -99.09 | -110.3 | -120.6 |
| EBIT 1 | -21.46 | -54.8 | -85.54 | -87.74 | -83.51 | -62.95 | -105.7 | -173.9 |
| Net income 1 | -20.52 | -49.04 | -97.09 | -84.71 | -88.45 | -58.83 | -137.2 | -173.1 |
| Net Debt 1 | - | - | - | -111.1 | -135.2 | -15.57 | -207.8 | -95.56 |
| Reference price 2 | 1.890 | 11.280 | 9.160 | 16.450 | 11.250 | 6.380 | 6.380 | 6.380 |
| Nbr of stocks (in thousands) | 15,015 | 36,968 | 39,644 | 49,146 | 53,729 | 71,071 | - | - |
| Announcement Date | 20-03-27 | 21-02-25 | 22-03-15 | 23-02-28 | 24-03-27 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -7.75x | 14.01x | -4.42x | - | 453M | ||
| 30.77x | 8.08x | 19.69x | -.--% | 124B | ||
| -237.72x | 10.39x | 136.77x | -.--% | 122B | ||
| -541.56x | 14.9x | -181.09x | -.--% | 32.94B | ||
| -41.18x | 3.33x | -9.59x | -.--% | 23.9B | ||
| -31.74x | 5.2x | -31.98x | -.--% | 20.54B | ||
| 22.48x | 4.48x | 14.67x | -.--% | 17.42B | ||
| 12x | 2.61x | 7.41x | +2.45% | 15.77B | ||
| -26.56x | - | - | -.--% | 14.26B | ||
| 70.87x | 6.51x | 80.19x | -.--% | 12.18B | ||
| Average | -75.04x | 7.72x | 3.52x | +0.27% | 38.26B | |
| Weighted average by Cap. | -113.73x | 8.53x | 36.81x | +0.10% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- ALT Stock
- Valuation Altimmune, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition